Baselaunch visual pills

BaseLaunch visual pills


Accelerating Therapeutic Ventures

We partner with scientists and entrepreneurs to help build biopharma ventures from scratch, getting the companies off the ground and financed. And we know how to do this – so far, our portfolio companies have raised over 100 million USD in financing.

What we do:

Grants for startups
Up to 500,000 USD in financing
Industry access for healthcare startups
Access to partners & network
Insights biotech and pharma ecosystem
Company & team build out
Infrastructure and laboratories healthcare startups
Access to infrastructure

Additional partners to be announced over the coming weeks and months.

Roivant
Bridge bio logo for site
“We are very pleased to continue our commitment to BaseLaunch. Basel has always been home to great ideas and innovation and today it is a leading life sciences hub within Switzerland and globally.”

James Sabry, Global Head of Roche Pharma Partnering

“We are delighted to join BaseLaunch as a partner in the next phase of its company building activities. The Pureos team worked closely with BaseLaunch during the Series A funding of Alentis Therapeutics and has been very impressed by the team and the quality of the selected programs."

Anja Harmeier, Partner at BB Pureos Bioventures

“We are proud to continue our partnership with BaseLaunch and support its mission of building companies that deliver innovative medicines to patients.”

Sascha Bucher, Head of Global Transactions at Roivant Sciences

News & Events

PharmaBiome AG, a pioneer in next-generation microbiome therapies recently extended its recent capital increase to a total of CHF 2.15 million. The pr...

Versameb AG is a biopharmaceutical company developing next-generation RNA-based therapeutics. The company’s unique proprietary technology platform g...

We are supporting an exciting project that exploits the role and vulnerabilities of circulating tumor cell clusters, major mediators of metastasis. Th...

From our partner, KPMG: Proving an online knowledge base for the COVID-19 times.  KPMG has put together an online resource page for these challenging...

Anaveon, a Basel-based immuno-oncology biotech, has successfully concluded a Series A financing round led by Syncona, a UK Life Sciences fund, and joi...

The Basel-based biotech company Alentis Therapeutics AG has successfully concluded a CHF 12.5 million Series A financing co-lead by BioMedPartners a...

T3 Pharma, a spin-off of the University of Basel and one of our portfolio, has raised over $12 million from Boehringer Ingelheim Venture Fund and Refe...

Basel-based biopharmaceutical Versameb has raised 6.4 million Swiss francs in a Seed C financing round and will put the funds towards expanding its te...

A strong and compelling pitch of your science is critical for your company’s survival.                                      ...

In preparation for the second Redefining Early Stage Investments (RESI) conference to be held in Europe, Life Science Nation (LSN) and Venture Valuati...

From our partner, KPGM: The rules of engagement in the global pharmaceutical industry are changing rapidly with disruption in this industry already we...

Lessons learned by startup founders Do you have an idea that could change the world? Is your project providing an innovative solution and holds the po...

The selection committee has chosen 15 promising projects for Phase I. The projects all focus on developing innovative technologies to dramat...